Three years into his tenure and with the COVID-19 pandemic behind him, Ionis Pharmaceuticals, Inc. CEO Brett Monia and the organization he helms have taken solid steps from being a platform technology company that out-licenses its drugs to becoming a fully integrated biotechnology company (FIBCO) that sells its own products.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
CEO Brett Monia Took The Helm At Start Of Transition
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
